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Background: To explore the outcomes and prognostic factors of ovarian metastasectomy intervention on overall
survival from extragenital primary cancer.
Methods: Patients with ovarian metastases from extragenital primary cancer confirmed by laparotomy surgery and
ovarian metastases resection were retrospectively collected in a single institution during an 8-year period. A total of
147 cases were identified and primary tumor sites were colorectal region (49.0%), gastric (40.8%), breast (8.2%),
biliary duct (1.4%) and liver (0.7%). The pathological and clinical features were evaluated. Patients’ outcome with
different primary tumor sites and predictive factors for overall survival were also investigated by univariate and
multivariate analysis.
Results: Metachronous ovarian metastasis occurred in 92 (62.6%) and synchronous in 55 (37.4%) patients.
Combined metastases occurred in 40 (27.2%). Bilateral metastasis was found in 97 (66%) patients. The median
ovarian metastasis tumor size was 9 cm. There were 39 (26.5%) patients with massive ascites ≥ 1000 mL on
intraoperative evaluation. With a median follow-up of 48 months, the median OS after ovarian metastasectomy
for all patients was 8.2 months (95% CI 7.2-9.3 months). In univariate analyses, there is significant (8.0 months vs.
41.0 months, P = 0.000) difference in OS between patients with gastrointestinal cancer origin from breast origin,
and between patients with gastric origin from colorectal origin (7.4 months vs. 8.8 months, P = 0.036). In univariate
analyses, synchronous metastases, locally invasion, massive intraoperative ascites (≥ 1000 mL), and combined
metastasis, were identified as significant poor prognostic factors. In multivariate analyses combined metastasis
(RR, 1.72; 95% CI, 1.09-2.69, P = 0.018), locally invasion (RR, 1.62; 95% CI, 1.03-2.54, P = 0.038) and massive
intraoperative ascites (RR, 1.58; 95% CI, 1.02-2.49, P = 0.04) were independent factors for predicting unfavorable
overall survival.
Conclusion: Ovarian metastases are more commonly originated from primary gastrointestinal tract. The prognosis
of ovarian metastasis is dismal and the benefit of ovarian metastatectomy is limited. Combined metastasis outside
ovaries, locally invasion and massive intraoperative ascites were independent factors for predicting unfavorable
overall survival. The identification of the primary tumor is required to plan for adequate treatment for this group
of patients.* Correspondence: zhonghuawang95@hotmail.com
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The differential diagnosis of an ovarian mass is complex
as approximately 7% of ovarian masses encountered
clinically are metastatic lesions, the most common sites
of origin being the gastrointestinal tract and breast.
Often time surgical exploration is necessary to arrive at
the correct diagnosis. The diagnosis and management of
patients with ovarian metastastic extragenital primary
cancer are typically challenging where inaccurate diag-
nosis has been reported in as many as 50% of the cases
even with thorough preoperative work-up due to the
presenting atypical symptoms [1-4]. Unlike the manage-
ment of primary ovarian cancer including maximum
tumor volume reduction which has demonstrated sur-
vival benefit [5,6] and CA125 as a predictive factor for
tumor recurrence and treatment response, the value
of similar surgical approach and post-surgery CA125
monitoring for metastatic ovarian tumor is uncertain
[7]. As the biological behavior and clinical outcome of
the ovarian metastatic lesions from extragenital cancer
origins are rarely summarized, we presented in this
study the characteristics and outcomes for all patients
with surgically confirmed ovarian metastases from extra-
genital primary cancer in a single institution during an
8-year period.
Methods
Patients who had undergone ovarian resection and diag-
nosed with ovarian metastases from extragenital tumor
between April 2003 and May 2011 were identified retro-
spectively from the database of the Department of Path-
ology at Fudan University Shanghai Cancer Center
(FUSCC). Chart review was performed for all cases for
verification of the availability of complete post-surgery
report, pathology report with immunohistochemistry
staining, complete treatment history for the primary can-
cer at our institute. 147 cases who met the above criteria
were included in our analysis. Clinical and pathological
variables including preoperative CA125, CEA and LDH
levels, intraoperative evaluation, size of ovarian metastases
of pathologic gross specimen, pathology reports, primary
tumor site, surgical procedures, and subsequent therapy at
the department of medical oncology for the primary can-
cer were collected. Overall survival (OS) was calculated
from the date of ovarian metastatectomy to death or last
follow-up time. In patients whose time interval between
the diagnosis of the primary tumor and that of the ovarian
metastasis exceeded 6 months were defined as metachro-
nous metastasis in current study.
Written informed consent for the use of patient infor-
mation in research analysis was obtained from all
patients at the time of admission as a routine practice at
FUSCC. The study had been approved by the FUSCC
Ethic Committee for Clinical Investigation.Statistical analysis
Survival analysis was carried out using life-table and
Kaplan-Meier method. Actuarial curves were compared
by the two-tailed log-rank test with a statistical signifi-
cance level of 0.05. The independent prognostic signifi-
cance of variables on the survival, proved to be
significant factor in univariate analysis, was tested in
proportional hazards regression models described by
Cox. The estimates of the models are given as hazard
ratio (HR) with 95% confidence intervals (95% CI).
Results
Characteristics of ovarian metastases
Clinical characteristics All patients’ characteristics were
listed in Table 1. The clinical characteristics of the
147 patients included in the analysis were listed in
Table 1. Patients were predominantly young with a
median age at diagnosis of 47 years old (range: 21-
78years), 81 (55.1%) being premenopausal. The most
common primary cancer were colorectal (72, 48.9%),
gastric (60, 40.8%), and breast (12, 8.2%). There were
more frequent colon (54/72, 75%) origins compared to
that of rectal (18/72, 25%). The majority of the cases
(105, 71.4%) presented high pre-operation serum CA125
level, 51 (34.7%) exhibited high pre-operation serum
CEA level and 28 (19%) patients had increased pre-
operation serum LDH level.
Among the 55 patients who had synchronous metasta-
sis, thirty-three patients (33/55, 60%) underwent syn-
chronous (16, 48.5%) or staged (17, 51.5%) primary
tumor resection with ovarian metastasectomy, and the
other 22 patients (22/55, 40%) received cytoreductive
surgery along with primary tumor resection because
of the presence of disease other than the ovaries.
92 patients ( 62.6%) had metachronous ovarian meta-
stasis, with a median time to metastasis of 15 months
(range: 7-203 months); the cumulative proportions of
time to metastasis within 1-year, 2-year and 3-year were
30.4%, 66.3%, 79.3%, respectively. Among the patients
with metachronous metastases, seventy-four patients
(74/92, 80.4%) underwent total resection of the meta-
static lesions, and the other 18 patients (18/92, 19.6%)
palliative oophorectomy.
One hundred and seven (72.8%) patients had ovarian
metastasis only while 40 (27.2%) patients had combined
metastases outside the ovaries, including liver, lung,
bone, lymph nodes and other distant organs. Among the
40 patients with combined metastases, 12 (30%) were
admitted with initial diagnosis of ovarian cancer for
tumor cytoreduction which turned to be gastrointestinal
tract or breast cancer originated; 17 (42.5%) were evalu-
ated to be resectable prior to surgery but extensive
abdominal and pelvic metastases were found during
the operation; palliative resection was conducted in














Biliary Duct 2 1.4
Liver 1 0.7
Timing of metastasis to ovary
Metachronous 92 62.6
Synchronous 55 37.4










≥1000 mL 39 26.5
<1000 mL 108 73.5
Size of ovarian metastases
Median (range) 9.0 (2.5-23cm)
≤5 cm 45 30.6
5-10 cm 48 32.7
>10 cm 54 36.7
Histologic type
Adenocarcinoma 91 61.9
Mucinous carcinoma 17 11.6
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The remaining 8 patients (20%) received the surgery due
to other unknown individual reasons.
Pathological characteristics Bilateral metastasis was
found in 97 (66%) patients. The median ovarian tumor
size was 9 cm (range: 2.5-23 cm); with 36.7% patients
>10cm. Thirty-nine patients (26.5%) were noted to have
massive intraoperative ascites ≥ 1000 mL. Forty-four
(29.9%) patients presented with metastatic disease con-
fined in the ovaries, while 103 (70.1%) varying degrees
of local invasion adjacent to the ovaries (including
mesentery, intestinal tube, peritoneum, omentum and
Douglas pouch). There were ninety-one (61.9%) adeno-
carcinoma, 39 (26.5%) signet ring cell carcinoma among
which 36 (92.3%) were gastric origin, 17 (11.6%) mucin-
ous carcinoma among which 14 (82.4%) were colorectal
cancer origin.
Prognosis of ovarian metastasectomy
With a median follow-up time of 48 months (range 3-
97 months), 110 patients (74.8%) died and 37 patients
(25.2%) were still alive. The median OS after ovarian
metastasectomy from extragenital primary cancer was
8.2 months (95% CI 7.2-9.3 months, Figure 1A).
In univariate analyses (Table 2), extragenital primary
cancer site from gastrointestinal cancer (vs breast cancer),
gastric cancer (vs colorectal cancer), synchronus metasta-
ses (vs metachronus), locally invasion ( vs none) com-
bined metastases (vs ovarian only), were identified as
significant poor prognostic factors, as shown in Table 2
and illustrated in Figure 1B to C. No correlation was
found between the numbers of positive locally invasion
sites (mesentery, intestinal tube, peritoneum, omentum
and Douglas pouch) and survival. Ovarian metastases
originated from gastrointestinal tract cancer, mucinous
carcinoma (N=38)and signet ring cell carcinoma(N=17)
seemed to be the pathological type that carried a poorer
prognosis, exhibiting a shorter survival trend with a
median OS of 7.6 mo, compared to that of adenocarcin-
oma cancer(N=76)of 8.5 mo (P= 0.076, data not shown
in Table 2).
Patients’ menopausal status, lateralality, size of the ovar-
ian metastases, pre-operation serum CA125, CEA and
LDH level were also analyzed in univariate analyses but
these factors were not prognostic indicators for survival
after the development of ovarian metastases (P> 0.05).
Figure 1 Overall survival and subgroup analysis in patients with ovarian metastasectomy from extragenital primary sites. A Overall
survival time, B Locally invasion, C Combined Metastases, D Massive ascites≥ 1000 mL.
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strated that combined metastasis (RR, 1.72; 95% CI,
1.09-2.69, P = 0.018), local invasion (RR, 1.62; 95% CI,
1.03-2.54, P = 0.038) and massive intraoperative ascites ≥
1000 mL (RR, 1.58; 95% CI, 1.02-2.49, P = 0.04) were in-
dependent factors for predicting unfavorable overall
survival (Table 3).
Discussion
The outcome and prognosis of 147 patients with surgi-
cally confirmed ovarian metastases from extragenital
primary cancer in our series reflected the complexity
and challenges for the management of this specific
population. 12 patients with initial preoperative diagno-
sis of primary ovarian cancer turned out to have ovarian
metastases from gastrointestinal tract or breast cancer.
The prognosis of ovarian metastases is dismal and
the benefit of ovarian metastatectomy remained to
be elucidated.The mechanism of ovarian metastasis has largely been
discussed in the literatures. Besides the commonly
described routes of metastases for metastastic ovarian
tumors arising from extragenital primary cancer that in-
clude direct invasion, surface implantation, other pos-
sible route for gastric cancer to disseminate to ovary
may include lymphatic drainage via the receptaculum
chili to the urogenital lymph vessel trunks, and,
hematogenous spread from gastrointestinal tract tumors
[8]. The lymphatic dissemination and transcoelomic
spread are also proposed to be important mechanisms
due to the high incidences of synchronized involvement
of peritoneum and lymph nodes in colorectal cancer [9].
The exact mechanism of the spread of breast cancer
to the ovaries had not been elucidated but the risk of
primary ovarian cancer is increased in women with
breast-ovarian cancer syndrome (BRCA1/2 mutation)
[10], lymphoma had been reported to spread to the
ovaries but there was none in our series [4].
Table 2 Univariate analysis for survival of ovarian









Colon & Rectum 49.0 8.8 6.5-11.2 0.036†
Stomach 40.8 7.4 6.3-8.4
Breast 8.2 41.0 2.0-85.0 0.000{
Biliary Duct 1.4 6.0
Liver 0.7 NR
Timing of metastasis to ovary
Metachronous 62.6 10.2 8.3-13.2 0.027
Synchronous 37.4 8.1 6.7-9.4
Combined with metastases outside ovaries
No 72.8 10.2 8.1-12.4 0.001
Yes 27.2 5.9 3.8-8.0
Locally invasion
No 70.7 13.7 6.4-21.0 0.007
Yes 29.3 8.0 7.1-9.0
Ascites
≥1000 mL 26.5 6.0 8.2-11.7 0.005
<1000 mL 73.5 9.9 3.5-8.5
†P value for colorectal cancer versus gastric cancer; { P value for breast cancer
versus gastrointestinal cancer.
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of colorectal origin compared to gastric origin, and more
frequently from colon rather than rectum [2,4,11-13].
Similar phenomenon was observed in our study. Nearly
half of our patients had primary cancer that arose from
colorectal cancer, and the ratio of colon to rectum was
3:1. Radiotherapy for rectal cancer with T3/4 or positive
lymph node disease may be the contributing factor as
ovarian micrometastases are eradicated and ovarian blood
supply is impaired, reducing the risk of ovarian spread.
Colonoscopy should not be omitted in cases presenting
with ovarian tumors as evident colorectal cancer-related
symptoms that may include defecate change or rectal
bleeding were rarely the initial presentation [14,15].Table 3 Multivariate analysis for survival
P value Relative
Risk
95% CI for Exp. B
lower upper
combined metastasis 0.018 1.72 1.095 2.688
Locally invasion 0.038 1.62 1.028 2.544
massive ascites≥ 1000 mL 0.04 1.58 1.02 2.495
Primary cancer site 0.068 0.77 0.59 1.02
Timing of metastasis to ovary 0.543 1.16 0.72 1.88
Histologic type 0.51 1.20 0.81 1.59The survival of the ovarian metastases patients from
extragenital tumors is related to the primary tumor
sites. In our series, patients with tumors originated
from breast exhibited the best median survival time of
41 months, followed by those of colorectal and stomach,
with the median survival time of 8.8 months and
7.4 months, respectively, which is comparable with pre-
vious data [16]. This result may be partly attributable to
the nature of breast cancer having a better prognosis
compared to the tumor from GI tract. Differences in
tumor biology among individual patients, tumor types,
or even within a given tumor, may also contribute to
survival. As is previously reported [12-17], the median
survival among patients with ovarian metastases of the
gastrointestinal cancer origin was 13-30 months. The
estimated 5-year disease free survival of the patients
without other metastastic lesions reached 40% after
complete resection [13]. However, the survival of the
patients with gastrointestinal origin in our series was
disappointing, with the median OS of 8.2 months. One
explanation could be due to the fact that nearly 40% of
the patients had synchronous ovarian metastases, repre-
senting a patient population of poorer prognosis. More-
over, the proportion of pathological type including
mucinous carcinoma and signet ring cell carcinoma was
nearly 40% in this cohort, which was also an unfavorable
survival factor. Another reason could be that 30% of the
patients were presented with combined extensive metas-
tases at the diagnosis, indicating worse prognosis as
found in other studies [13,15,16].. Peritoneal dissemin-
ation was reported as an adverse factor influencing
the survival time [15]. In our analysis, huge volume of
ascites and high incidence of local invasion were also
determined as a poor prognostic factor. Additionally, the
finding that there was no survival difference based on
tumor size and laterality indicates that the development
of ovarian metastases is a sign of a more aggressive dis-
ease and the ovarian metastases are diagnosed late in the
cancer disease process.
Therefore, whether maximal surgical debulking should
be conducted was controversial. Aggressive therapeutic
measures similar to the practice for primary ovarian can-
cer had been advocated, especially in the case of colorec-
tal cancer with ovarian metastases which was less
responsive to chemotherapy [18,19]. Bilateral oophorec-
tomy for ovarian metastasis from colorectal cancer have
been shown to have a positive impact on disease-free
and overall survival in isolated ovarian metastases
patients in an Italian study [20]. Also, for patients with
gastric cancer, a Korean study suggested that debulking
or gastrectomy plus metastasectomy may bring survival
benefits for patients with distant metastases who were
receiving systemic chemotherapy [21]. However, other
believed that metastatectomy should be reserved for
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spread via a transcoelomic route and hence, a harbinger
of peritoneal metastasis [9,22,23]. It remains unclear
whether prophylactic bilateral oophorectomy would
improve the survival, and routine practice of prophy-
lactic bilateral oophorectomy may not be justified as to
the low frequency of isolated ovarian involvement with-
out distant metastases [9]. The effect of metastatectomy
could not be determined in this study with its small
sample size and retrospective in nature. Variability of
distant metastatic status besides the ovaries and surgical
procedures would bias the evaluation of surgery-related
quality of life and long-term survival. In our study, it
appeared that palliative surgery did not improve the
long-term survival and well-designed prospective trials
focusing on this aspect is needed to resolved the issue.
Effective methods have to be introduced, as traditional
tumor marker in ovarian tumor, CA125, was not specific
in predicting the survival of patients with ovarian metas-
tases from extragenital cancer. PET/CT may be consid-
ered as an alternative approach in search for primary
tumor sites and it was reported that a variable maximum
SUV in ovarian metastases may be correlated to dif-
ferent primary origins [24].
Conclusion
Ovarian metastases are more commonly seen to origin-
ate from primary gastrointestinal tract in our study. The
prognosis of ovarian metastasis is dismal and the benefit
of ovarian metastatectomy is limited. Those with com-
bined metastasis outside ovaries, locally invasion and
massive intraoperative ascites were independent factors
for predicting unfavorable overall survival. The identifica-
tion of the primary tumor is required to plan for adequate
treatment for this group of patients. Image scanning
and gastrointestinal endoscopy should be recommended
before the ovarian metastatectomy.
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